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The calcineurin/nuclear factor of activated T cells (NFATs) signaling pathway plays a central role in T cell mediated
adaptive immune responses, but a number of recent studies demonstrated that calcineurin/NFAT signaling also
plays a key role in the control of the innate immune response by myeloid cells. Calcineurin inhibitors, such as
cyclosporine A (CsA) and tacrolimus (FK506), are commonly used in organ transplantation to prevent graft rejection
and in a variety of immune diseases. These immunosuppressive drugs have adverse effects and significantly
increase host’s susceptibility towards bacterial or fungal infections. Recent studies highlighted the role of NFAT
signaling in fungal infection and in the control of the pattern recognition receptor nucleotide-binding
oligomerization domain-containing protein 1 (NOD1), which predominantly senses invasive Gram-negative bacteria
and mediates neutrophil phagocytic functions. This review summarises some of the current knowledge concerning
the role of NFAT signaling in the innate immune response and the recent advances on NFAT-dependent inhibition
of NOD1-mediated innate immune response caused by CsA, which may contribute to sensitizing transplant
recipients to bacterial infection.
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Calcineurin inhibitors, such as cyclosporine A (CsA) and
its newer counterpart FK506 (also called tacrolimus), are
potent immunosuppressive drugs widely used to prevent
acute graft rejection and in the treatment of a variety of
autoimmune disorders. In addition to their potent in-
hibitory action on T cell receptor-mediated activation of
the adaptive immune system, calcineurin inhibitors have
many adverse side effects [1]. CsA, which is nephrotoxic,
may induce chronic allograft nephropathy [2,3]. Long-
term immunosuppressive treatment also favours the oc-
currence of fungal and bacterial infection [4-6]. Urinary
tract infection (UTI), whether complicated by acute py-
elonephritis (APN) or not, usually due to uropathogenic
Escherichia coli (UPEC), represents the most frequent
infectious complication after renal transplantation [4].
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article, unless otherwise stated.relatively benign, a number of studies have suggested
that they may increase the risk of graft loss and com-
promise long-term graft outcome [7,8]. Many factors con-
tribute to the occurrence of post-transplantation UTI/
APN. Combined effects of calcineurin inhibitors with lipo-
polysaccharide (LPS) endotoxins, rejection episodes, or re-
current UTIs may contribute to allograft injury during
UTI/APN [9-11]. However, the mechanism(s) by which
calcineurin inhibitors could directly modulate host-fungal
or -bacterial interactions has remained largely unknown,
until recent studies that have provided lines of evidence
that the NFAT/calcineurin pathway, which interferes with
the development of the myeloid lineage [12], plays impor-
tant roles in the regulatory mechanisms of the immune
innate system against pathogens.
The immune system recognizes a large variety of micro-
organisms and microbial-associated molecular patterns
(MAMPs) through different pattern recognition receptors
(PRRs) expressed by immune cells, such as polymorpho-
nuclear neutrophils (PMNs), macrophages, natural killer
(NK) cells, and dendritic cells (DCs), and also a variety ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tion of MAMPs by PRRs, either present on the plasma
membrane or in the cytosolic compartment, is essential for
the removal of bacterial pathogens [15]. Once activated,
PRRs initiate signaling cascades leading to the activation of
the transcription factor NF-κB and mitogen-associated pro-
tein kinases (MAPKs). The subsequent production of pro-
inflammatory mediators will then induce the activation and
recruitment of immune cells, which play a key role in the
first line of defence to kill invasive pathogens.
Several families of PRRs have been identified. They in-
clude Toll-like receptors (TLRs), NOD-like receptors
(NLRs), RIG-like helicase (RLRs), and AIM2-like receptors
(ALRs) [16-18]. TLRs are transmembrane receptors, which
recognize a large variety of MAMPS in human and murine
species. Among them, TLR2 forming heterodimers with
TLR1 or TLR6 senses bacterial lipopeptides. TLR3 recog-
nizes double-stranded RNA from viruses, TLR4 senses
lipopolysaccharide from Gram-negative bacteria, TLR5 rec-
ognizes flagellin from flagellated bacteria, TLR7 recognizes
single stranded RNA in endosomes, and TLR9 senses
hypomethylated microbial DNA [19]. UPEC colonizing the
urinary tract are recognized by several TLRs, including
TLR2, 4, 5, 11, and perhaps 9 [20]. TLR11 is expressed in
murine bladder epithelial cells and renal tubule cells, but
is only represented by a pseudogene in humans [21].
Among NLRs, the nucleotide-binding oligomerization
domain-containing protein 1 (NOD1) and 2 (NOD2) are
two intracellular receptors that play important roles in the
recognition of invasive pathogens [13,22].
Recently, interactions between the NFAT/calcineurin sig-
naling pathways and PRRs have been established suggesting
possible dysregulation of the innate immune response that
could explain the greater susceptibility of transplanted
patients treated with calcineurin inhibitors to fungal or
bacterial infections. In addition, several groups have
highlighted the role of the NOD1 receptor in the activa-
tion of neutrophil phagocytic functions against pathogenic
bacteria, and shown that inhibition of NFAT/calcineurin
signaling in myeloid cells could account for altered Nod1-
mediated microbicide innate immune response.
This review will focus on the recent advances on the
role of NFAT/calcineurin signaling and its interplay with
NOD1-mediated phagocytic functions in the regulation of
innate immune responses in myeloid cells, and on the ad-
verse effects of calcineurin inhibitors on altered NFAT/
calcineurin-dependent innate immune response, which may
sensitize kidney grafts to fungal and bacterial infections.
The NFAT/calcineurin signaling pathway and
innate immunity
The Ca2+/calmodulin/calcineurin pathway regulates the
activity of the transcription factors of the nuclear factor
of activated T cells (NFAT) family. The NFAT familyencompasses five individually encoded members. NFAT1
(also called NFATc2 or NFATp), NFAT2 (NFATc1 or
NFATc), NFAT3 (NFATc4), NFAT4 (NFATc3 or NFATx)
[23], and NFAT5 (also called TonEBP or OREBP) [24].
All NFATs share a similar DNA-binding domain, and
are modulated by calcineurin, a calcium, calmodulin-
dependent serine/threonine protein phosphatase, con-
sisting of a catalytic subunit calcineurin A (CnA), and a
tightly associated Ca2+-binding subunit, calcineurin B
(CnB) [25]. NFAT5, which differs in its structure from
the other NFATs, is not regulated by calcium, but is acti-
vated in response to osmotic stress. NFATs are main-
tained in an inactive state in the cytosol of resting cells.
Upon the stimulation of intracellular Ca2+ influx, cal-
modulin is activated and dephosphorylates the phos-
phorylation motifs from the N-terminus of NFATs,
allowing NFATs to translocate to the nucleus where they
collaborate with other transcription factors, such as AP-1,
to induce gene transcription [26]. Calcineurin inhibitors,
which inhibit the phosphatase activity of calcineurin and
the nuclear translocation of NFATs, are currently used to
prevent graft rejection in transplant recipients. Impaired
activation of NFATs will prevent the transcription of cyto-
kine genes, including IL-2, in activated T cells [26]. How-
ever, in addition to their major functions in lymphocytes
in adaptive immunity, new roles of NFATs in innate im-
munity have been identified in myeloid cells [27].
Dectin-1, which plays a key role in the recognition of
pathogenic fungi, is a β-glucan receptor belonging to the C-
type lectin receptors, and is activated by zymosan, a cell-
wall constituent of Candida species [28-30]. Upon ligand
activation, dectin-1 cooperates with TLR2 to stimulate NF-
κB and regulate cytokine production [31]. Dectin-1 alone
was shown to induce phagocytosis and Src and Syk
kinases-mediated induction of reactive oxygen species
(ROS) via the activation of NFAT in macrophages and DCs
[32]. Dectin-1 also regulates the induction of members of
early growth response (Egr) family, cyclooxygenase-2
(COX2), and IL-2, IL-10, and IL-12 p70 productions by
DCs stimulated by zymosan [32]. CD14 was also shown to
induce Ca2+ influx and NFAT activation causing apoptosis
of differentiated DCs, but not macrophages, stimulated by
LPS [33]. NFAT2/c1 activated by the receptor activator of
NF-κB (RANKL) was also shown to play a key regulatory
role in the terminal differentiation of osteoclasts [34].
Recently, Fric et al. [12] demonstrated that NFAT1/c2
acts as a negative regulator of myeloid lineage development.
These authors showed that inhibition of calcineurin/NFAT
signaling increases the number of myeloid progenitors, and
that the two calcineurin inhibitors CsA and FK506 antago-
nized the development of DCs induced by the Fms-related
tyrosine kinase 3 ligand (Flt3-L). These findings demon-
strated that calcineurin/NFAT signaling contributes to
maintenance of innate immune homeostasis [35].
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direct evidence that NFAT/calcineurin pathways interfere
with the regulatory mechanisms of innate immune de-
fences. Calcineurin inhibitors or knockdown of calcineurin
mRNA expression activate NF-κB and TLR-mediated
MAPK pathways in macrophages, while over-expression
of a constitutively activated form of the CnA subunit in-
hibits TLR- activated pathways [36]. The development of
selective inhibitors of NFAT, such as VIVIT, a high-affinity
calcineurin-binding peptide selected from combinatorial
peptide libraries based on the calcineurin docking site of
NFAT [37], and the more recent cell permeable inhibitor
of NFAT, 11R-VIVIT [38] have proved to be useful tools
to analyse in vivo the functions of NFAT. 11R-VIVIT and
FK506 significantly inhibit LPS and LPS plus IFN-γ in-
duced IL-12 expression independently of IL-10 in macro-
phages, whereas in vivo administration of 11R-VIVIT was
shown to significantly improve inflammatory lesions in an
experimental model of colitis [39]. The leucine-rich repeat
kinase 2 (LRRK2), identified as a major susceptibility gene
for Crohn’s disease [40,41], was reported to act as a nega-
tive regulator of NFAT1/c2-induced cytokine responses.
LRRK2 modulates the cytoplasm retention of NFAT and
the interaction between NFAT1 and the non coding RNA
NFAT repressor (NRON) complex [42] in response to in-
ducer of the innate immunity [43]. Furthermore, severe
experimental colitis induced by dextran sulphate sodium
(DSS) in LRRK2 deficient (Lrrk2-/-) mice was associated
with enhanced nuclear localization of NFAT1. VIVIT was
also shown to inhibit TNF-α induced expression in mouse
bone marrow macrophages (BMMs) stimulated by the
TLR4 ligand, LPS, and the TLR1/2 ligand, Pam3CSK4. In
addition, LPS stimulation did not induce the nuclear trans-
location of NFAT1/c2 and NFAT2/c1, but in contrast,
BMMs exhibited constitutive nuclear localization of
NFAT4/c3 and NFAT3/c4, regardless of LPS stimulation.
Moreover, VIVIT removed NFAT4 and NFAT3 from the
nucleus and inhibited TLR-mediated activation of TNF
[44]. Overall, these findings have highlighted regulatory
roles of NFATs on different aspects of the immune re-
sponse, and suggest that the NFATs may have distinct func-
tions according to the cell type or pathogen considered.
Although the regulatory role of NFAT1 and other
NFATs has been extensively studied in myeloid cells, only
a few studies have analysed the expression and the role of
NFAT/calcineurin signaling in neutrophils. Vega et al. [45]
first reported the expression of NFAT2/c1 in human
PMNs. Antigens, anti-IgE, and anti-FcεR induced Ca2+
stimulation, which increases cellular calcineurin activity
and the nuclear translocation of NFAT2/c1, while CsA
and VIVIT abolished antigens- and anti-IgE-induced
cyclooxygenase-2 (COX2) upregulation and prostaglandin
E2 (PGE2) release [45]. Greenblatt et al. [46] also evi-
denced NFAT2/c1 and NFAT4/c3 expression in murinePMNs, and showed that mice with a conditional deletion
of CnB in neutrophils, like CsA-treated mice, failed to
control C. albicans infection without affecting the classical
fungicidal activity, including ROS production and phago-
cytosis in response to C. albicans or zymosan stimulation.
However, both CsA-treated neutrophils and CnB-deficient
neutrophils exhibited impaired production of IL-10 after
stimulation by zymosan and curdlan, which is the specific
dectin-ligand with no TLR2 and TLR4 stimulating proper-
ties [46]. Altogether, these findings evidenced a novel, not
yet fully characterized, NFAT-dependent and -independent
candidacidal mechanism beyond dectin-1 that could ac-
count for the disseminated fungal infections observed in
CsA-treated patients, independently of the effect of the im-
munosuppressive drugs on the adaptive immune response
[46]. Recently, we also showed that knockdown of NFAT2/
c1 mRNA expression by silencing mRNAs, similar to the
inhibitory action of the 11R-VIVIT on NFATs, markedly
inhibited the Nod1 mRNA expression without affecting
Tlr2 and Tlr4 mRNA expressions in mouse macrophages
activated by UPEC [47]. In vivo administration of CsA or
FK506 (AV, ET, MB, CC, and CW, unpublished results), or
11R-VIVIT also markedly impaired the neutrophil bacterial
phagocytic killing capacity of UPEC and increased the renal
susceptibility to UPEC using an experimental murine
model of ascending UTI [47]. These findings indicate that
CsA may directly alter NOD1 expression and E. coli killing
capacity by neutrophils. In line with these findings, a num-
ber of recent studies have provided evidence that NOD1
plays an important role in the regulation of neutrophil
phagocytic function, which represents the main first line of
defence against pathogenic bacteria. Figure 1 illustrates the
participation of NFATc in the activation of the innate im-
mune response in myeloid cells in response to various ef-
fectors. The following paragraphs will summarise the
current knowledge of how NOD1 takes part in the regula-
tion of the immune innate response to invasive pathogenic
bacteria.
NOD1 signaling
NOD1 (CARD4) belongs to the NLR family of multi-
domain protein, including NOD2 (CARD15), and consists
of an amino-terminal caspase activation and recruitment
domain (CARD), a nucleotide-binding oligomerization do-
main (NBD), and a C-terminal leucine-rich repeat domain
(LRR) [48,49], that is also found in TLRs and that has been
linked to resistance to infections [48]. The binding of
MAMPs to the LRR domain results in the activation of
signaling through homophilic CARD-CARD interactions
[49,50]. NOD1 contains a single CARD domain, while
NOD2 contains two domains [51]. NOD1 and NOD2 are
two intracellular receptors that recognize bacterial pep-
tidoglycan fragments. NOD1 recognizes γ-D-glutamyl-
meso-diaminopimelic acid (meso-DAP), a degradation
Figure 1 Differential activation of NFATc in myeloid cells. Schematic representation of the activation and inhibition of NFATc by calcineurin
inhibitors in myeloid cells. (A) Inhibition of calcineurin/NFAT signaling by cyclosporine A (CsA) or the NFAT peptide inhibitor, VIVIT, antagonizes
Flt3-L-induced development of bone marrow myeloid cells and increases the number and proliferation of myeloid progenitors [12] (B) Antigens- and
anti-IgE-dependent activation of NFAT2/c1 and up-regulation of COX2 expression and release of PGE2. CsA and the peptide inhibitor of NFAT, VIVIT,
both inhibited antigens- and anti-IgE-mediated activation of COX2 and PGE2 in human neutrophils [45]. (C) LPS activates NFAT3/c4 and NFAT4/c3 in
mouse macrophages, and CsA and VIVIT both induced significant inhibition of the LPS-induced TNF production [44]. (D) Zymosan and curdlan failed
to activate IL-10, COX2, Egr1 and Egr2 expressions regulated by NFAT2/c1 and NFAT4/c3 in CsA-treated and CnB-deficient neutrophils, indicating that
the dectin-1 receptor is the upstream activator of calcineurin. C. albicans killing was not affected in NFAT-deficient neutrophils, suggesting that the CnB
regulation of antifungal response may occur through an NFAT-independent anti-microbial mechanism [46]. (E) Downexpression of the NFAT2/c1 by
silencing RNA (siRNA) impaired the activation of NOD1 induced by UPEC. CsA or the cell permeable 11R-VIVIT inhibited the UPEC-induced NOD1
expression and NOD1-mediated neutrophil functions (migration capacity, phagocytosis, bacterial killing) [47]. DC: Dendritic cell; MΦ: Macrophage;
PMN: Polymorphonuclear neutrophil.
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which is present in most Gram-negative bacteria, such as
Shigella flexneri, enteroinvasive and uropathogenic E. coli,
Chlamydia, or Pseudomonas aeruginosa [47,54-57], Heli-
cobacter pylori [58], and some Gram-positive bacteria
[59,60]. In contrast, NOD2 recognizes muramyl dipeptide
(MDP), a motif common to PGNs from all classes of bac-
teria [61]. NOD1 is ubiquitously expressed, while NOD2
is mainly found in macrophages, DCs, Paneth cells, and a
variety of epithelial cells [13]. Mutations in the CARD15
gene encoding NOD2 have been shown to be associated
with Crohn’s disease, a chronic inflammatory bowel dis-
ease mainly driven by T cells [62,63].Upon ligand recognition, the NBD domain of NOD1 or
NOD2 oligomerizes and initiates the interaction of the
CARD domain with RIPK2 (also called RIP2/RICK), which
is a member of the CARD protein family [49,55]. RIPK2 is
activated subsequently by proximity and promotes the for-
mation of a signaling complex that contains the regulatory
subunit of the IKK complex, NEMO [64], leading to
NF-κB activation (see Figure 2, left panel). NOD1 also in-
duces the activation of c-Jun NH2-terminal kinase (JNK)
pathway [55,65] and apoptosis [66]. NOD1 activating
ligands were shown to enter cells through an endocytic
process, most likely in a clathrin-dependent manner,
and the cytosolic internalization of NOD1 ligands is
Figure 2 NOD1 signaling and interactions with Rho GTPases and NFATc. (Left panel) Schematic representation of the activation of NOD1
interacting with Caspase recruitment domain (CARD)-containing kinase RIPK2, which leads to activation of RIPK2 and subsequent recruitment and
activation of TAK1. The TAK1 complex then induces the polyubiquitination of the IKK-β kinase, degradation of the NF-κB repressor IκB, nuclear
translocation of NF-Kb, and transcription of pro-inflammatory mediators. NOD1 stimulating agonists also activate JNK. The guanine exchanger
SopE from salmonella activates Rho GTPase Rac1 and Cdc42, which form a protein complex with NOD1 and the heat shock protein 90 (not
shown). Activation of Rac1 and Cdc42 induces the activation of NOD1/RIPK2 signaling and induction of NF-κB-mediated pro-inflammatory
mediators. Downregulation of NOD1 expression by calcineurin inhibitors or silencing NFATc1 mRNA markedly impairs bacterial-mediated activation of
PMN functions (e.g. neutrophil migration and E. coli phagocytic killing capacities). (Right panel) Schematic view of the NFATc activation pathway by cell
surface receptors coupled to Ca2+ mobilization. Ca2+-dependent activation of calmodulin (CaM) and calcineurin B (CnB) enables CaM binding to CnA
regulatory region, and CnA activating conformational change. Activated calcineurin then dephosphorylates the phosphorylation motifs of NFATc,
allowing NFATc to translocate to the nucleus. Nuclear NFATc, in collaboration with other transcription factors (such as AP-1), then induce gene
transcription. Calcineurin activity is inhibited by CsA or FK506, which binds to their intracellular immunophillin receptors. The high-affinity
calcineurin-binding VIVIT peptides are potent blockers of NFATc. IKK: I kappa B kinase; JNK: c-Jun N-terminal kinases; NEMO: NF-κB essential modulator;
NF-κB: nuclear factor κB; RIPK2: Receptor-interacting serine/threonine-protein kinase 2; TAK1: Transforming growth factor-beta-activated kinase 1;
TCR: T cell receptor.
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in the cytosol and plasma membrane of human intestinal
cells, and imaging studies revealed that NOD1 is recruited
to the site of entry of invasive S. flexneri [68].
NOD1 regulates neutrophil phagocytic functions
The rapid production of chemokines by immune cells and
epithelial cells induces the rapid recruitment of poly-
morphonuclear neutrophils (PMNs) to the site of inflam-
mation, which represent the first line of defence of the
innate immune system against extracellular pathogens
[69]. Masumoto et al. [70] first reported that the adminis-
tration of the synthetic NOD1 ligand KF1B in WT mice
induced the rapid production of CCL2/MCP1 and
CXCL2/MIP-2 and the recruitment of intraperitoneal
PMNs, but not lymphocytes and macrophages. This effect
appeared to be NOD1-dependent since the recruitment of
PMNs induced by the active NOD1-stimulatory com-
pound KF1 was abolished in NOD1 deficient (Nod1-/-)
mice. Dharancy et al. [71] also showed that upon liver in-
jury induced by carbon tetrachloride (CCL4) intoxication,the in vitro migration capacity of PMNs induced by che-
moattractants chemokines or formyl-methionyl-leucyl-
phenylalanine (fMLP) was significantly reduced in Nod1-/-
PMNs compared to WT PMNs. These authors also
showed that the number of infiltrating PMNs was lower in
the liver from Nod1-/- mice than WT mice subjected to
ischemia-reperfusion injury. Conversely, FK565, another
potent synthetic NOD1 agonist [72], significantly stimu-
lated the migration of PMNs [71]. Nod1-/- mice were also
shown to exhibit impaired production of CXCL1 and de-
fective recruitment of neutrophils to the intestine after
Clostridium difficile infection, suggesting that NOD1-
mediated neutrophil recruitment regulates susceptibility
towards C. difficile in the intestine [60]. We also showed
using a murine model of ascending UTI that Nod1-/-, but
not Nod2-/- mice, were more susceptible than WT mice to
the retrograde inoculation of UPEC, and exhibited im-
paired recruitment of neutrophils in the UPEC-infected
kidneys [47].
The process governing PMN extravasation from blood
vessels involves a complex multistep cascade that is
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interactions with vessel wall endothelial cells. The recruit-
ment of PMNs involves a cascade of adhesive and migra-
tory events, including the capture and selectin-mediated
rolling of PMNs along the vessels, chemokine-induced ac-
tivation of PMNs, and integrin-dependent adhesion and
subsequent trans-endothelial migration [73-76]. Surface
expression levels of the β2-integrin CD11b/CD18 de-
creased from about 50% in liver PMNs from CCL4-treated
Nod1-/- mice compared to that of their WT counterparts,
and fMLP failed to activate CD11b expression in Nod1-/-
neutrophils [71]. In contrast, the synthetic agonist FK565
increased β2-integrin expression in neutrophils infiltrating
injured liver after CCL4 intoxication. Renal bacterial loads
were also significantly greater in the infected kidneys from
Nod1-/- mice than from their WT counterparts, 24 h after
the transurethral inoculation of UPEC [47]. Like that oc-
curring in Nod1-/- livers subjected to ischemia [71], the
number of GR1high+, CD11bhigh+ neutrophils was also sig-
nificantly less in kidneys from infected Nod1-/- mice than
in WT mice, 24 h after UPEC infection [47].
The Weiser group demonstrated that NOD1 is involved
in the phagocytic killing capacity of bone marrow-derived
neutrophils [77]. This group showed, using a mouse model
of airway bacterial co-infection with the Gram-positive
pathogen Streptococcus pneumoniae and Gram-negative
Haemophilus influenzae (Hi), that neutrophils from mice
treated with the Gram-negative bacteria H. influenzae
containing synthetic PGN fragments containing meso-
DAP, activate cytoplasmic NOD1 and facilitate neutrophil
opsonophagocytic killing of the Gram-positive Streptococ-
cus pneumoniae [78]. Clarke et al. [79] then demonstrated
that PGN can translocate from the gut into bone marrow
cells, and that in vivo administration of a synthetic NOD1
ligand, but not the NOD2 ligand MDP, can restore neutro-
phil phagocytic functions after antibiotic-induced micro-
biota depletion [79]. These authors also showed that
Nod1-/- mice were more susceptible than WT mice to S.
pneumoniae infection. Overall, these findings have pro-
vided clear evidence that PGN, through NOD1, can stimu-
late innate immunity in mouse neutrophils. These results
are relevant to humans, since we found, ex vivo, in PMNs
of human transplant patients a downregulation of NOD1
mRNA associated with reduced E. coli phagocytosis pro-
perties [47].
NOD1 interacts with Rho GTPases to stimulate the innate
immune response
The mechanism by which NOD1 stimulates bacterial
phagocytosis has been first attributed to a priming effect
of the immune system [79], but recent studies evidenced
close interplay between NOD1 and the small Rho
GTPases [80]. Activated Rho GTPases Rac1 and Rac2, and
Cdc42 [81,82], which lead to rapid actin rearrangements,play key roles in the activation of phagocytic processes
[83]. Rac1 was shown to regulate PGN activation of the
NF-κB signaling pathway through the recruitment of the
p85 regulatory phosphoinositide 3-kinase (PI3K) subunit
in macrophages [84]. Pathogenic bacteria also synthesize a
number of virulent factors activating or mimicking small
Rho GTPase proteins in host cells [85]. Most of the factors
activating Rho GTPases have been identified in Gram-
negative bacteria, such as the cytotoxic necrotizing Factor
1 (CNF1) expressed in UPEC strains, or the Salmonella
outer protein E (SopE/SopE2) from S. Typhimurium [86].
These factors were shown to stimulate the innate immune
response. For example, SopE/SopE2 and SopB from S.
Typhimurium stimulate Rho GTPases leading to NF-κB
and MAPKs activation [87]. The guanine nucleotide ex-
change factor H1 (GEF-H1) from S. flexneri, which inter-
acts with NOD1, was shown to be required for the RIK2-
dependent activation of NF-κB [88]. Boyer et al. [89] also
showed that the E. coli cytotoxic necrotizing factor 1
(CNF1), the prototypal bacterial toxin activating host
GTPases, activates Rac2, which then interacts with the in-
nate immune adaptors IMD (the fly ortholog of RIP1/
RIPK2), and RIP1 and RIPK2 to induce NF-κB activation
and IL-8 expression in mammalian cells. Keestra et al. [90]
using a mouse model of S. Typhimurium infection and
transfected HEK293 cells, have shown that the activation of
Rac1 and Cdc42 by bacterial delivery or SopE expression
stimulate NOD1 signaling and downstream RIPK2-
mediated stimulation of the NF-κB inflammatory response.
These authors also showed that PGN detects NOD1 by
sensing the activation of Rac1. These findings, which are
summarised in the left panel from Figure 2, have provided
the first direct demonstration that pathogen-induced
NOD1 signaling requires small Rho GTPases.
Cyclosporine A impairs NFAT/NOD1-mediated renal
antibacterial defence
The impact of immunosuppressive therapy, which in-
creases susceptibility towards bacterial infection has been
considered for a long time to be largely non specific. How-
ever, former studies have provided indirect evidence that
calcineurin inhibitors may affect neutrophil functions
[91-94]. The decreased renal susceptibility to UPEC fol-
lowing CsA treatment has been attributed to NFATc1-
dependent inhibition of NOD1-mediated innate immune
response [47]. Figure 2 summarises the main sites of in-
hibitory action of CsA and FK506, and VIVIT peptides on
the Ca2+-dependent calcineurin/NFAT signaling leading to
the activation of NFAT activated genes, such as IL-2. The
inhibitory effects of these agents on NOD1 signaling path-
way and subsequent activation of neutrophil functions are
also shown.
CsA may differently affect immune receptors. CsA,
which inhibits Nod1 mRNA expression in myeloid cells,
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Nod1 and Nod2 expression in renal tubule cells, suggest-
ing that the combined decrease in TLR4 mRNA and
protein expression in renal tubule cells and in NOD1 in
myeloid cells caused by CsA should contribute to the
observed decreased resistance to UPEC [47]. Immunosup-
pressant therapy increases the susceptibility towards bac-
terial and viral infection, which explains the incidence of
infectious events in solid organ recipients. However, the
concentrations of calcineurin inhibitors generally used
in vitro are generally about 10-fold higher than those used
in humans to prevent activation of lymphoid cells. The
question arises as to whether or not the concentration of
calcineurin inhibitors used during current immunosup-
pressive regimens are sufficient to fully suppress NFATc in
myeloid cells. We reported that incubating murine mye-
loid cells with a concentration of 100 nM (~ 120 ng/ml)
CsA, which is in the same range as the serum concentra-
tions of CsA found in renal transplant recipients, mark-
edly downregulated the expression of NOD1 (but not of
TLR2 and TLR4). Clinical studies also evidenced a similar
decrease in NOD1 mRNA and functional response in leu-
kocytes from transplant recipients treated with CsA [47].
These findings suggest that low concentrations of CsA can
be sufficient to impair NFAT activation and/or nuclear
residence. By contrast to the observation that FK506 can
induce reduced responsiveness to LPS in DCs and macro-
phages [95], Tourneur et al. [47] did not evidence marked
decrease in either LPS- or Pam3CSK4-induced IL-8 pro-
duction in intact leukocytes from transplant recipients re-
ceiving CsA. Given that interplays between NODs and
TLRs can be critical for the induction of protective im-
mune responses [52,96], it cannot be excluded that the
possible induction of TLR4 tolerance together with de-
creased NOD1-mediated phagocytic functions caused by
calcineurin inhibitors contribute to impaired resistance of
transplant recipients to UPEC colonizing renal grafts. A
better understanding of the mechanism of activation of
small Rho GTPases and NOD1 by virulent effectors pro-
duced by pathogens should provide new insights in the
mechanisms triggering bacterial phagocytosis.
Conclusion
A number of studies have recently defined new roles in
the regulation by calcineurin/NFAT signaling of the innate
immune system in myeloid cells and provided a better un-
derstanding of the altered immune response caused by
calcineurin inhibitors relevant to the frequency of dissemi-
nated fungal infection and UTI/APN seen in renal trans-
plant recipients. The consequence of activating NFAT
signaling may differ depending on the cell type and effec-
tors considered. Although our understanding of the regu-
lation of NFAT signaling has been greatly improved, the
redundant role of the different NFATc proteins stillrenders difficult in vivo studies on the exact function of
the different NFAT signaling pathways. The development
of pharmacological strategies aimed at specifically inhibit-
ing NFAT activation, such as VIVIT peptides, also remains
limited and should deserve further studies to assess the
use of such peptide inhibitors in vivo.
Given that calcineurin inhibitors that interact with
NFAT are still used in the prevention of graft rejection and
in the treatment of chronic autoimmune disorders, the de-
velopment of new strategies aimed to reduce the occur-
rence of bacterial or fungal infection still remains justified.
Because CsA and FK506 remain indispensable for prevent-
ing transplant rejection, different strategies have been de-
veloped to decrease their adverse effects by reducing the
concentrations of calcineurin inhibitors alone or in com-
bination with other suppressive drugs [mycophenolate
mofetyl (Cellcept), rapamycin (a potent mTOR inhibitor)
or monoclonal antibodies [97]. As also stated by Zanoni
and Granucci [98], a better understanding of the specific
role of the NFATc proteins differently expressed in im-
mune cells, and the development of new tools allowing
more specific in vivo inhibition of the different NFATc
should provide a basis for the development of drugs with
more specific actions than CsA or FK506.
A number of studies have provided convincing evidence
that pre-treatment of mice with NOD agonists enhances
host protection against sepsis, bacterial infection, viruses,
or even parasites [99]. Given that NOD1 synthetic agonists
can restore NOD1-mediated host protective functions in
CsA-treated mice [47], the administration of synthetic
NOD1 agonists alone or in combination with antibiotics
might be potentially helpful to reduce the occurrence of
ascending UTI and APN in renal graft. The immunopro-
tective effect of the NOD1 agonists, which restored the
renal defence of CsA-treated mice against invasive UPEC
[47], certainly results from their immunostimulatory prop-
erties, which enhance host protective functions by in-
creasing the levels of protective factors. However, the
exact mechanism of NOD1 activation by synthetic
NOD1 agonists remains largely unknown. In addition,
further studies should be required to determine the tim-
ing of prophylactic effects provided by NOD1 ligands
on neutrophil functions to avoid blunting of their innate
immune capacities.
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